Abbott Laboratories (NYSE:ABT) Given "Buy (B)" Rating at Weiss Ratings

Key Points

• Abbott Laboratories received a "Buy (B)" rating from Weiss Ratings, reaffirming investor confidence in the company's stock.
• Several analysts adjusted their price targets for Abbott, with a consensus average target price of $146.24 and an overall rating of "Moderate Buy."
• For Q2 2025, Abbott Laboratories has guided EPS between $5.100 and $5.200, based on a recent quarterly earnings report showcasing a revenue increase of 7.4% year-over-year.

Abbott Laboratories (NYSE:ABT - Get Free Report)'s stock had its "buy (b)" rating reaffirmed by Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently weighed in on ABT. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Evercore ISI upped their price target on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an "outperform" rating in a research note on Tuesday. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Finally, Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $146.24.

Abbott Laboratories Stock Performance

NYSE ABT traded up $0.34 on Wednesday, hitting $133.36. 1,357,464 shares of the company's stock were exchanged, compared to its average volume of 6,579,862. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm's 50-day moving average price is $132.19 and its two-hundred day moving average price is $131.45. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The firm has a market cap of $232.10 billion, a price-to-earnings ratio of 16.70, a P/E/G ratio of 2.54 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter last year, the business posted $1.14 earnings per share. Abbott Laboratories's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.46% of the stock is owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several hedge funds have recently modified their holdings of ABT. IMG Wealth Management Inc. boosted its position in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after buying an additional 167 shares during the period. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories during the first quarter worth about $27,000. Abound Financial LLC acquired a new stake in Abbott Laboratories during the first quarter valued at approximately $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the 1st quarter valued at $30,000. Finally, Anfield Capital Management LLC raised its position in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.